On February 9, 2022 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8th. Joseph J. Wolk, Executive Vice President and Chief Financial Officer, will represent the Company in a session scheduled at 1:05 p.m. (Eastern Time) (Press release, Johnson & Johnson, FEB 9, 2022, View Source;johnson-to-participate-in-the-raymond-james-43rd-annual-institutional-investors-conference-301479192.html [SID1234607931]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately 48-hrs after the live webcast.